| Gene symbol | HIF1A | Synonyms | HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1, PASD8, bHLHe78 | Type of gene | protein-coding |
| Chromosome | 14 | Map location | 14q23.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | hypoxia inducible factor 1 subunit alpha | ||||
| GTO ID | GTC1270 |
| Trial ID | NCT00466583 |
| Disease | Lymphoma |
| Altered gene | HIF1A |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | EZN-2968 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia-Inducible Factor-1alpha, Administered as a Weekly 2-Hour Intravenous Infusion in Adult Patients With Advanced Solid Tumors or Lymphoma |
| Year | 2007 |
| Country | United States |
| Company sponsor | Enzon Pharmaceuticals, Inc. |
| Other ID(s) | EZN-2968-01 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||